Table 2 Baseline demographics and disease characteristics for patients with vasodilatory shock
| Â | Baseline angiotensin I/II ratio | P value | |
|---|---|---|---|
<1.63 (n = 141) | ≥1.63 (n = 140) | ||
Age, years | |||
 Median (IQR) | 65 (51–76) | 63 (53–75) | 0.522 |
Sex (male/female), % | 58.9%/41.1% | 61.4%/38.6% | 0.715 |
Baseline MAP, mmHg | |||
 Median (IQR) | 66.3 (63.3–68.7) | 67 (63.7–68.7) | 0.891 |
APACHE II | |||
 Median (IQR) | 27 (22–33) | 29 (23–34) | 0.112 |
Albumin (g/dL) | |||
 Median (IQR) | 2.2 (1.7–2.7) | 2.4 (2.0–2.8) | 0.007 |
SCVO2, % | |||
 Median (IQR) | 77 (73.0–83.0) | 76.5 (72.2–82.0) | 0.211 |
Central venous pressure (mmHg) | |||
 Median (IQR) | 12 (10–15) | 12 (10–16) | 0.317 |
Cardiac index | |||
 Median (IQR) | 3.1 (2.6–4.0) | 3.1 (2.8–3.7) | 0.796 |
MELD score | |||
 Median (IQR) | 22 (15–25) | 23 (17–28) | 0.046 |
Chest X-ray finding of ARDS, n (%) | 44 (31.2%) | 33 (23.7%) | 0.182 |
Medical history of ARDS, n (%) | 33 (23.4%) | 15 (10.7%) | 0.007 |
Exposure to ACE inhibitors, n (%) | 1 (0.7%) | 27 (19.3%) | < 0.001 |
Exposure to ARBs, n (%) | 13 (9.2%) | 7 (5.0%) | 0.246 |
AKI with dialysis/CRRT, n (%) | 39 (27.7%) | 52 (37.1%) | 0.098 |
Vasopressin use during 6 h before randomization, n (%) | 93 (66.0%) | 102 (72.9%) | 0.244 |
Baseline norepinephrine-equivalent dose (μg/kg/min) | |||
 Median (IQR) | 0.30 (0.22–0.49) | 0.39 (0.24–0.59) | 0.006 |
Median (IQR) ANG I level, (pg/mL) | 134 (42.7–468) | 354.5 (129–869.5) | < 0.001 |
Median (IQR) ANG II level, (pg/mL) | 164 (45–552) | 42.35 (11.5–134.5) | < 0.001 |
Median ANG I/II ratio (IQR) | 0.98 (0.67–1.21) | 5.36 (2.64–14.73) | < 0.001 |